OPL Stock Overview
Engages in the development of digital tools that enhance healthcare experience for patients in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Opyl Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.016 |
| 52 Week High | AU$0.042 |
| 52 Week Low | AU$0.016 |
| Beta | 1.89 |
| 11 Month Change | -5.88% |
| 3 Month Change | -42.86% |
| 1 Year Change | n/a |
| 33 Year Change | -88.15% |
| 5 Year Change | -89.33% |
| Change since IPO | -99.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| OPL | AU Software | AU Market | |
|---|---|---|---|
| 7D | -5.9% | 3.2% | -1.1% |
| 1Y | n/a | 66.5% | 16.1% |
Return vs Industry: Insufficient data to determine how OPL performed against the Australian Software industry.
Return vs Market: Insufficient data to determine how OPL performed against the Australian Market.
Price Volatility
| OPL volatility | |
|---|---|
| OPL Average Weekly Movement | n/a |
| Software Industry Average Movement | 8.9% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 3.6% |
Stable Share Price: OPL's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: Insufficient data to determine OPL's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | n/a | Saurabh Jain | www.opyl.ai |
Opyl Limited engages in the development of digital tools that enhance healthcare experience for patients in Australia. The company offers TrialKey, an AI-driven clinical trial optimization and success prediction platform, that simulate and optimize trial designs for pharmaceuticals, medical devices, alternative therapies, and novel conditions. It also provides TrialGen, an AI-powered tool streamlines clinical trial design process for biopharma, MedTech, government, and healthcare organizations.
Opyl Limited Fundamentals Summary
| OPL fundamental statistics | |
|---|---|
| Market cap | AU$2.73m |
| Earnings (TTM) | -AU$3.13m |
| Revenue (TTM) | AU$397.64k |
6.9x
P/S Ratio-0.9x
P/E RatioIs OPL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OPL income statement (TTM) | |
|---|---|
| Revenue | AU$397.64k |
| Cost of Revenue | AU$1.80m |
| Gross Profit | -AU$1.40m |
| Other Expenses | AU$1.73m |
| Earnings | -AU$3.13m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.018 |
| Gross Margin | -351.77% |
| Net Profit Margin | -787.24% |
| Debt/Equity Ratio | 0% |
How did OPL perform over the long term?
See historical performance and comparison